Granzyme B PET Imaging Reveals Lgmn + Macrophage‐Mediated Immune Evasion and Guides Immunotherapy in EGFR‐TKI‐Resistant NSCLC
Open Access
- 16 September 2026
- journal article
- research article
- Published by Wiley in Advanced Science
- p. e77837
Abstract
Determining optimal therapies for EGFR‐mutant NSCLC after tyrosine kinase inhibitor (TKI) resistance remains challenging. Immune checkpoint inhibitors (ICIs) show limited efficacy, but some patients regain immunotherapy sensitivity post‐TKI. Non‐invasive monitoring to identify responders and understand persistent immune tolerance is needed. In this study, we prospectively evaluated a novel granzyme B‐targeted PET radiotracer, 68 Ga‐GZB, in a clinical cohort of NSCLC patients. 68 Ga‐GZB PET/CT accurately visualized early immune responses and stratified patients likely to benefit from immunotherapy. In preclinical models of acquired EGFR‐TKI resistance, we tracked dynamic immune reactivity via 68 Ga‐GZB PET/CT. Single‐cell transcriptomics and functional validation identified Lgmn + macrophages as a highly immunosuppressive subset driving persistent immunotherapy tolerance. Mechanistically, Lgmn + macrophages secrete extracellular vesicles (EVs) that deliver Lgmn directly into CD8 + T cells. Internalized Lgmn recruits the E3 ubiquitin ligase Chip, initiating the ubiquitination and proteasomal degradation of the glycolytic enzyme Eno1. This cascade severely impairs CD8 + T cell glycolysis, ultimately leading to CD8 + T cell exhaustion. Furthermore, we demonstrate that targeting of Lgmn synergizes with PD‐1 blockade to reactivate anti‐tumor immunity in TKI‐resistant models. Thus, 68 Ga‐GZB PET/CT provides a non‐invasive platform to stratify immunotherapy responses, and targeting Lgmn represents a novel combination strategy for EGFR‐TKI‐resistant NSCLC.Keywords
Funding Information
- National Natural Science Foundation of China (82272035)
- National Natural Science Foundation of China (U23A20465)
- National Natural Science Foundation of China (82502397)
- National Natural Science Foundation of China (12275057)
- China Postdoctoral Science Foundation (2025M772252)
This publication has 16 references indexed in Scilit:
- Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancerCell Metabolism, 2024
- Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerCancer Cell, 2024
- In vivo clinical molecular imaging of T cell activityTrends in Immunology, 2023
- Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?Journal of Thoracic Oncology, 2021
- MiR-690, an exosomal-derived miRNA from M2-polarized macrophages, improves insulin sensitivity in obese miceCell Metabolism, 2021
- Targeting macrophages: therapeutic approaches in cancerNature Reviews Drug Discovery, 2018
- Primary, Adaptive, and Acquired Resistance to Cancer ImmunotherapyCell, 2017
- Tumour-associated macrophages as treatment targets in oncologyNature Reviews Clinical Oncology, 2017
- Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapyAnnals of Oncology, 2016
- Perforin and granzymes: function, dysfunction and human pathologyNature Reviews Immunology, 2015